{
  "company": {
    "ticker": "VRTX",
    "name": "Vertex Pharmaceuticals Inc.",
    "category": [
      "Biotech"
    ],
    "sector": "Healthcare",
    "subCategory": "Biotech",
    "cik": "0000875320"
  },
  "reports": [
    {
      "filing": {
        "accessionNumber": "0000875320-25-000232",
        "filingDate": "2025-11-04",
        "reportDate": "2025-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/vrtx-20250930.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "raised",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 3076.4,
        "netIncome": 1082.9,
        "operatingCashFlow": 3133.4,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 182,
        "marketShareMention": "More than three quarters of approximately 94,000 CF patients in U.S., Europe, Australia and Canada treated with Vertex medicines",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United_States": 64.2,
          "Europe": 27.2,
          "Other": 8.6
        },
        "capexAmount": 288.2,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics collaboration for gene-editing therapies",
          "Zai Lab partnership for povetacicept in China/Asia",
          "Ono Pharmaceuticals partnership for povetacicept in Japan/Korea"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": true,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex delivered strong Q3 2025 financial results, driven by continued growth in cystic fibrosis franchise and successful launches of ALYFTREK, CASGEVY, and JOURNAVX. The company maintains a robust pipeline across multiple therapeutic areas and continues to expand its global market presence.",
        "keyQuotes": [
          "We expect that the number of people with CF taking our medicines will continue to grow through new approvals and reimbursement agreements",
          "We have begun our commercial launch of JOURNAVX in the U.S. for eligible adults"
        ],
        "marketData": {
          "priceOnEarningsDate": 391.6400146484375,
          "priceAfter7Days": 410.2799987792969,
          "priceChangePercent": 4.759468755405876,
          "managementToneScore": 100,
          "earningsBeatScore": 50,
          "priceActionScore": 65,
          "guidanceAccuracyScoreWeighted": 90,
          "compositeSentimentScore": 68,
          "compositeSentiment": "bullish"
        }
      },
      "quarter": "Q3 2025",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2025,
        "fiscalQuarter": 3,
        "fiscalYear": 2025,
        "quarter": "Q3 2025",
        "reportDate": "2025-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-25-000216",
        "filingDate": "2025-08-05",
        "reportDate": "2025-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532025000216/vrtx-20250630.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "raised",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "stable",
        "revenue": 2944,
        "netIncome": 1032.9,
        "operatingCashFlow": 1892,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 146.9,
        "marketShareMention": "Treating more than three quarters of approximately 94,000 CF patients in U.S., Europe, Australia, and Canada",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United_States": 62.1,
          "Europe": 30.9,
          "Other": 7
        },
        "capexAmount": 186.4,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics (gene-editing)",
          "Moderna (CFTR mRNA therapy)",
          "Zai Lab (povetacicept licensing)",
          "Ono Pharmaceuticals (povetacicept licensing)",
          "CRISPR Therapeutics AG",
          "Alphine Immune Sciences Inc",
          "Entrada Therapeutics",
          "Zai Lab Limited",
          "Ono Pharmaceuticals Co. Ltd."
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": true,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex delivered strong Q2 2025 financial results, with product revenues increasing to $2.9 billion driven by continued demand for TRIKAFTA/KAFTRIO and early contributions from new product launches. The company continues to expand its commercial footprint across cystic fibrosis, sickle cell disease, and acute pain markets.",
        "keyQuotes": [
          "We expect that the number of people with CF taking our medicines will continue to grow through new approvals and reimbursement agreements",
          "We have begun our commercial launch of JOURNAVX in the U.S. for eligible adults",
          "We continue to advance a diversified pipeline of potentially transformative medicines for serious diseases"
        ],
        "marketData": {
          "priceOnEarningsDate": 445.20001220703125,
          "priceAfter7Days": 459.4100036621094,
          "priceChangePercent": 3.1918218925093056,
          "managementToneScore": 100,
          "earningsBeatScore": 50,
          "priceActionScore": 65,
          "guidanceAccuracyScoreWeighted": 90,
          "compositeSentimentScore": 68,
          "compositeSentiment": "bullish"
        }
      },
      "quarter": "Q2 2025",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2025,
        "fiscalQuarter": 2,
        "fiscalYear": 2025,
        "quarter": "Q2 2025",
        "reportDate": "2025-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-25-000192",
        "filingDate": "2025-05-06",
        "reportDate": "2025-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532025000192/vrtx-20250331.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 2770.2,
        "netIncome": 646.3,
        "operatingCashFlow": 818.9,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 228.4,
        "marketShareMention": "Treating nearly three quarters of approximately 94,000 CF patients in US, Europe, Australia, and Canada",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United_States": 59.8,
          "Europe": 29.8,
          "Other": 10.4
        },
        "capexAmount": 40.7,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics collaboration",
          "Moderna collaboration for VX-522 nebulized CFTR mRNA therapy",
          "Entrada Therapeutics license for myotonic dystrophy program",
          "Zai Lab collaboration for povetacicept in Asia"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex delivered strong Q1 2025 results, driven by continued TRIKAFTA/KAFTRIO performance and initial contributions from ALYFTREK. The company continues to expand its CF portfolio, launch CASGEVY for sickle cell disease, and advance a diversified pipeline across multiple therapeutic areas.",
        "keyQuotes": [
          "We expect to grow our CF business by increasing the number of people with CF who are eligible and able to receive our medicines.",
          "We continue to advance a diversified pipeline of potentially transformative medicines for serious diseases utilizing a range of modalities."
        ],
        "marketData": {
          "priceOnEarningsDate": 484.82000732421875,
          "priceAfter7Days": 474.55999755859375,
          "priceChangePercent": -2.1162513119562156,
          "managementToneScore": 85,
          "earningsBeatScore": 50,
          "priceActionScore": 45,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 52,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q1 2025",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2025,
        "fiscalQuarter": 1,
        "fiscalYear": 2025,
        "quarter": "Q1 2025",
        "reportDate": "2025-03-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-25-000053",
        "filingDate": "2025-02-13",
        "reportDate": "2024-12-31",
        "form": "10-K",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/vrtx-20241231.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "stable",
        "revenue": null,
        "netIncome": null,
        "operatingCashFlow": null,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "Competitive landscape in multiple therapeutic areas like CF, SCD, pain, with multiple companies developing potential competing therapies",
        "customerConcentration": null,
        "geographicBreakdown": null,
        "capexAmount": null,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR",
          "Moderna",
          "Entrada",
          "Zai",
          "CRISPR Therapeutics AG",
          "Zai Lab Limited",
          "Alpinine Immune Sciences Inc",
          "Entrada Therapeutics",
          "Editas Medicine Inc",
          "Septerna Inc",
          "Catalyst Biosciences"
        ],
        "supplyChainStatus": "tight",
        "regulatoryHeadwinds": [
          "Evolving cell and gene therapy regulatory requirements",
          "Complex manufacturing and approval processes",
          "Potential drug pricing regulations"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "neutral",
        "summary": "Vertex continues to focus on developing therapies across multiple disease areas including cystic fibrosis, sickle cell disease, and pain. The company faces complex regulatory challenges and competitive pressures but maintains a robust pipeline and strategic partnerships.",
        "keyQuotes": [
          "Our success depends on our ability to successfully develop and commercialize additional products",
          "We continue to invest significant resources in the research and development of therapies for serious diseases and conditions"
        ],
        "marketData": {
          "priceOnEarningsDate": 402.70001220703125,
          "priceAfter7Days": 408.32000732421875,
          "priceChangePercent": 1.3955785812835326,
          "managementToneScore": 70,
          "earningsBeatScore": 50,
          "priceActionScore": 55,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 54,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q4 2024",
      "quarterInfo": {
        "calendarQuarter": 4,
        "calendarYear": 2024,
        "fiscalQuarter": 4,
        "fiscalYear": 2024,
        "quarter": "Q4 2024",
        "reportDate": "2024-12-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-24-000223",
        "filingDate": "2024-11-05",
        "reportDate": "2024-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532024000223/vrtx-20240930.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "raised",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 2771.9,
        "netIncome": 1045.4,
        "operatingCashFlow": -1077.2,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 220,
        "marketShareMention": "Treating nearly three quarters of approximately 92,000 people with CF in North America, Europe, and Australia",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United States": 61.8,
          "Europe": 30.6,
          "Other": 7.6
        },
        "capexAmount": 205.1,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics collaboration",
          "Moderna collaboration for CF mRNA therapy",
          "Alpine Immune Sciences acquisition"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex demonstrated strong quarterly performance driven by continued growth in its cystic fibrosis franchise and the recent launch of CASGEVY for sickle cell disease and beta thalassemia. The company is preparing for potential near-term product launches and continues to invest heavily in R&D across multiple therapeutic areas.",
        "keyQuotes": [
          "We are evaluating our CF medicines in additional patient populations, with the goal of having small molecule treatments for all people who have at least one mutation in their CFTR gene",
          "We estimate approximately 35,000 people with severe SCD or TDT could be eligible for CASGEVY in the U.S. and Europe"
        ],
        "marketData": {
          "priceOnEarningsDate": 465.0799865722656,
          "priceAfter7Days": 448.6000061035156,
          "priceChangePercent": -3.543472293918906,
          "managementToneScore": 100,
          "earningsBeatScore": 50,
          "priceActionScore": 35,
          "guidanceAccuracyScoreWeighted": 70,
          "compositeSentimentScore": 55,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q3 2024",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2024,
        "fiscalQuarter": 3,
        "fiscalYear": 2024,
        "quarter": "Q3 2024",
        "reportDate": "2024-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-24-000198",
        "filingDate": "2024-08-02",
        "reportDate": "2024-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532024000198/vrtx-20240630.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 2645.6,
        "netIncome": -3593.6,
        "operatingCashFlow": -2447,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 128.3,
        "marketShareMention": "Nearly three quarters of ~92,000 people with CF in North America, Europe, and Australia treated with Vertex CF medicines",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United_States": 61,
          "Europe": 30.5,
          "Other": 8.5
        },
        "capexAmount": 137.4,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics (gene-editing therapies)",
          "Moderna (mRNA CF therapy)",
          "Alpine Immune Sciences (acquired for $5B)",
          "CRISPR Therapeutics AG",
          "Alprine Immune Sciences Inc",
          "Entrada Therapeutics"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "neutral",
        "summary": "Vertex delivered strong CF product revenues of $2.6B in Q2, driven by TRIKAFTA's performance and continued global expansion. The company made a significant $5B acquisition of Alpine Immune Sciences and is preparing for potential launches in CF and acute pain.",
        "keyQuotes": [
          "We expect to grow our CF business with label expansions, continued uptake in younger patient groups, and growth in the number of people living with CF.",
          "We continue to advance a diversified pipeline of potentially transformative medicines for serious diseases utilizing a range of modalities."
        ],
        "marketData": {
          "priceOnEarningsDate": 471.25,
          "priceAfter7Days": 481.8900146484375,
          "priceChangePercent": 2.2578280421087533,
          "managementToneScore": 65,
          "earningsBeatScore": 50,
          "priceActionScore": 55,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 53,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q2 2024",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2024,
        "fiscalQuarter": 2,
        "fiscalYear": 2024,
        "quarter": "Q2 2024",
        "reportDate": "2024-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-24-000139",
        "filingDate": "2024-05-07",
        "reportDate": "2024-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532024000139/vrtx-20240331.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "raised",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 2690.6,
        "netIncome": 1099.6,
        "operatingCashFlow": 1306.6,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 275.8,
        "marketShareMention": "Treating nearly three quarters of ~92,000 people with CF in North America, Europe, and Australia",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United_States": 56.5,
          "Europe": 36,
          "Other": 7.5
        },
        "capexAmount": 68.4,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics (gene editing)",
          "Moderna (mRNA therapy)",
          "Alpine Immune Sciences (pending acquisition)"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": true,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex delivered strong Q1 2024 results driven by continued CF product growth and successful launches of CASGEVY. The company is preparing for near-term launches in CF and acute pain while maintaining a robust pipeline across multiple therapeutic areas.",
        "keyQuotes": [
          "We expect to grow our CF business with continued uptake, label expansions, and growth in the number of people living with CF",
          "Our strategy is to combine transformative advances in the understanding of causal human biology and the science of therapeutics to discover and develop innovative medicines"
        ],
        "marketData": {
          "priceOnEarningsDate": 420.4800109863281,
          "priceAfter7Days": 404.2200012207031,
          "priceChangePercent": -3.8670113538771034,
          "managementToneScore": 100,
          "earningsBeatScore": 50,
          "priceActionScore": 35,
          "guidanceAccuracyScoreWeighted": 90,
          "compositeSentimentScore": 59,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q1 2024",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2024,
        "fiscalQuarter": 1,
        "fiscalYear": 2024,
        "quarter": "Q1 2024",
        "reportDate": "2024-03-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-24-000062",
        "filingDate": "2024-02-15",
        "reportDate": "2023-12-31",
        "form": "10-K",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532024000062/vrtx-20231231.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "weak",
        "headcountTrend": "expanding",
        "revenue": 9426.9926485,
        "netIncome": 1869.9973492000001,
        "operatingCashFlow": null,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "Concentrated revenues from CF medicines, facing increasing competition",
        "customerConcentration": null,
        "geographicBreakdown": null,
        "capexAmount": null,
        "capexGrowth": null,
        "partnerships": [
          "Lonza (cell therapy manufacturing)",
          "CRISPR",
          "Moderna",
          "Entrada"
        ],
        "supplyChainStatus": "tight",
        "regulatoryHeadwinds": [
          "IRA drug pricing negotiations",
          "State drug pricing transparency laws",
          "Potential changes to healthcare regulations"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "neutral",
        "summary": "Vertex maintains a strong financial position with $9.4B in revenue and $1.87B in net income, primarily driven by cystic fibrosis medicines. The company is expanding into cell and genetic therapies like CASGEVY while navigating complex regulatory and pricing challenges.",
        "keyQuotes": [
          "We remain focused on ensuring the stability of supply chains for our current products",
          "Cell and genetic therapies require significant investment to secure capacity at third parties with expertise",
          "We are investing significant resources in expanding and strengthening our manufacturing capabilities"
        ],
        "marketData": {
          "priceOnEarningsDate": 410.9100036621094,
          "priceAfter7Days": 419.1199951171875,
          "priceChangePercent": 1.9980023318753728,
          "managementToneScore": 65,
          "earningsBeatScore": 50,
          "priceActionScore": 55,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 53,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q4 2023",
      "quarterInfo": {
        "calendarQuarter": 4,
        "calendarYear": 2023,
        "fiscalQuarter": 4,
        "fiscalYear": 2023,
        "quarter": "Q4 2023",
        "reportDate": "2023-12-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-23-000031",
        "filingDate": "2023-11-07",
        "reportDate": "2023-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532023000031/vrtx-20230930.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "raised",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 2483.5,
        "netIncome": 1035.3,
        "operatingCashFlow": 3302.7,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 157.1,
        "marketShareMention": "Treating more than two-thirds of CF patients in North America, Europe, and Australia",
        "customerConcentration": null,
        "geographicBreakdown": {
          "United States": 62.6,
          "Europe": 30.9,
          "Other": 6.5
        },
        "capexAmount": 142.3,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics (gene editing)",
          "Moderna (CFTR mRNA therapeutic)",
          "Entrada Therapeutics (myotonic dystrophy)",
          "Verve Therapeutics (liver gene editing)"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex demonstrated strong Q3 performance with robust cystic fibrosis product sales and expanding pipeline across multiple therapeutic areas. The company continues to invest in innovative research and development, with near-term launch opportunities in sickle cell disease, beta thalassemia, and acute pain.",
        "keyQuotes": [
          "We are preparing for near-term launches of potential new products in sickle cell disease, beta thalassemia, CF and acute pain.",
          "We continue to advance a diversified pipeline of potentially transformative medicines for serious diseases utilizing a range of modalities."
        ],
        "marketData": {
          "priceOnEarningsDate": 347.8299865722656,
          "priceAfter7Days": 355.20001220703125,
          "priceChangePercent": 2.1188586146336807,
          "managementToneScore": 100,
          "earningsBeatScore": 50,
          "priceActionScore": 55,
          "guidanceAccuracyScoreWeighted": 70,
          "compositeSentimentScore": 61,
          "compositeSentiment": "bullish"
        }
      },
      "quarter": "Q3 2023",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2023,
        "fiscalQuarter": 3,
        "fiscalYear": 2023,
        "quarter": "Q3 2023",
        "reportDate": "2023-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-23-000021",
        "filingDate": "2023-08-02",
        "reportDate": "2023-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532023000021/vrtx-20230630.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 2493.2,
        "netIncome": 915.7,
        "operatingCashFlow": 2034.3,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 179.1,
        "marketShareMention": "Collectively, our four medicines are being used to treat more than two-thirds of the approximately 88,000 people with CF in North America, Europe, and Australia.",
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 60.5,
          "Europe": 32.1,
          "Other": 7.4
        },
        "capexAmount": 101.7,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics collaboration for gene-editing therapies",
          "Moderna collaboration for CFTR mRNA therapeutic",
          "Lonza manufacturing agreement for stem cell therapies"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex delivered strong quarterly performance with $2.5B in product revenues, driven by continued uptake of TRIKAFTA/KAFTRIO. The company is advancing multiple pipeline programs across cystic fibrosis, gene therapies, and other serious diseases while maintaining robust financial health.",
        "keyQuotes": [
          "We are preparing for near-term launches of potential new products in sickle cell disease, beta thalassemia, CF and acute pain.",
          "We continue to advance a diversified pipeline of potentially transformative small molecule, mRNA, cell and genetic therapies aimed at treating serious diseases."
        ],
        "marketData": {
          "priceOnEarningsDate": 351.9100036621094,
          "priceAfter7Days": 338.17999267578125,
          "priceChangePercent": -3.90156882255361,
          "managementToneScore": 100,
          "earningsBeatScore": 50,
          "priceActionScore": 35,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 51,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q2 2023",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2023,
        "fiscalQuarter": 2,
        "fiscalYear": 2023,
        "quarter": "Q2 2023",
        "reportDate": "2023-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875320-23-000012",
        "filingDate": "2023-05-02",
        "reportDate": "2023-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532023000012/vrtx-20230331.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "expanding",
        "revenue": 2374.8,
        "netIncome": 699.8,
        "operatingCashFlow": 899.9,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 236.4,
        "marketShareMention": "Collectively, our four medicines are being used to treat more than two-thirds of the approximately 88,000 people with CF in North America, Europe, and Australia",
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 59.1,
          "Europe": 34,
          "Other": 6.9
        },
        "capexAmount": 42.1,
        "capexGrowth": null,
        "partnerships": [
          "CRISPR Therapeutics collaboration",
          "Moderna collaboration for VX-522 CFTR mRNA therapeutic",
          "Entrada Therapeutics collaboration for DM1 therapeutics"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Vertex delivered strong Q1 performance with $2.4B in revenue driven by TRIKAFTA/KAFTRIO uptake. The company continues to expand its CF franchise and advance pipeline programs in multiple therapeutic areas including sickle cell disease, beta thalassemia, and type 1 diabetes.",
        "keyQuotes": [
          "We expect to grow our CF business with continued uptake, label expansions, and development of new therapies",
          "We are preparing for near-term launches of potential new products in sickle cell disease, beta thalassemia, CF and acute pain"
        ],
        "marketData": {}
      },
      "quarter": "Q1 2023",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2023,
        "fiscalQuarter": 1,
        "fiscalYear": 2023,
        "quarter": "Q1 2023",
        "reportDate": "2023-03-31"
      },
      "analyzedSuccessfully": true
    }
  ],
  "totalFetched": 12,
  "successfulAnalyses": 11,
  "lastUpdated": "2025-11-26T06:06:59.049Z"
}